Arvinas, Pfizer to out-license commercialization rights to vepdegestrant

Arvinas (ARVN) provided an update on its collaboration with Pfizer (PFE) for the co-development of vepdegestrant, an investigational oral Protac estrogen receptor protein degrader, and announced additional corporate actions. Arvinas and Pfizer have jointly agreed to out-license the commercialization rights to vepdegestrant to a third party. Together, the companies have begun seeking a partner with the capabilities and expertise to maximize the commercial potential of vepdegestrant, if approved, for patients with ESR1-mutant, ER+/HER2- advanced or metastatic breast cancer and potentially develop vepdegestrant in new settings. Vepdegestrant is currently under review by the FDA as a monotherapy in the treatment of estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. The FDA has assigned a Prescription Drug User Fee Act action date of June 5, 2026.